ATRIDOX GEL (CONTROLLED-RELEASE)

Država: Kanada

Jezik: engleski

Izvor: Health Canada

Kupi sada

Svojstava lijeka Svojstava lijeka (SPC)
28-06-2021

Aktivni sastojci:

DOXYCYCLINE (DOXYCYCLINE HYCLATE)

Dostupno od:

DEN-MAT HOLDINGS, LLC

ATC koda:

A01AB22

INN (International ime):

DOXYCYCLINE

Doziranje:

8.8%

Farmaceutski oblik:

GEL (CONTROLLED-RELEASE)

Sastav:

DOXYCYCLINE (DOXYCYCLINE HYCLATE) 8.8%

Administracija rute:

SUBGINGIVAL

Jedinice u paketu:

250ML

Tip recepta:

Prescription

Područje terapije:

ANTIBACTERIALS

Proizvod sažetak:

Active ingredient group (AIG) number: 0105569007; AHFS:

Status autorizacije:

APPROVED

Datum autorizacije:

2000-07-05

Svojstava lijeka

                                PM-001 ATRIDOX
®
_Product Monograph_
Page 1 of 27
ECR#27139
Rev Date: 23 June 2021
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
PR
ATRIDOX
® CONTROLLED-RELEASE DOXYCYCLINE GEL
8.8% w/w Doxycycline (as Hyclate)
in DOXYGEL™ Delivery System
Antimicrobial Agent for Periodontitis
Manufactured by:
Den-Mat Holdings, LLC
Date of Initial Approval:
1017 W. Central Ave.
July 5, 2000
Lompoc, CA 93436
U.S.A.
Imported by:
Date of Revision:
Radiant Global Logistics
June 28, 2021
3520 Laird Rd., unit 4
Mississauga, Ontario,
Canada L5L 5Z7
Distributed by:
Henry Schein
345 Townline Rd
Niagara on the Lake,
ON, L0S 1J0, CA
Submission Control No: 242758
PM-001 ATRIDOX
®
_Product Monograph_
Page 2 of 27
ECR#27139
Rev Date: 23 June 2021
RECENT MAJOR LABEL CHANGES
Not Applicable
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
................................................................. 4
1
INDICATIONS................................................................................................................
4
1.1
Pediatrics............................................................................................................
4
1.2
Geriatrics
............................................................................................................
4
2
CONTRAINDICATIONS
.................................................................................................
4
3
SERIOUS WARNINGS AND PRECAUTIONS BOX
........................................................ 4
4
DOSAGE AND
ADMINISTRATION.................................................................................
4
4.1
Dosing Considerations
........................................................................................
4
4.2
Recommended Dose and Dosage Adjustment
..................................................... 5
4.3
Administration
.....................................................................................................
5
4.4
Reconstitution
.......................................................................
                                
                                Pročitajte cijeli dokument
                                
                            

Dokumenti na drugim jezicima

Svojstava lijeka Svojstava lijeka francuski 06-07-2020

Upozorenja za pretraživanje vezana za ovaj proizvod